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Age-related macular degeneration (AMD) is the pri-
mary cause of irreversible photoreceptors loss in
adult patients and current therapies are limited. In-
creased levels of matrix metalloproteinases (MMPs)
have been documented in neovascularization of se-
vere ocular pathologies such as AMD and proliferative
diabetic retinopathy. We report here that MMP-9 (ge-
latinase B) expression is induced and temporally reg-
ulated in the course of experimental choroidal neo-
vascularization. We used transgenic mice expressing
-galactosidase reporter gene under the dependence
of MMP-9 promoter and RT-PCR analysis on choroidal
neovascular structures microdissected from serial
sections by laser pressure catapulting to show that
MMP-9 expression is up-regulated concomitantly with
the appearance of inflammatory cells in the subreti-
nal lesion. In mice deficient in MMP-9 expression the
development of choroidal neovascularization in-
duced by laser photocoagulation still occurred, but at
a reduced level. (Am J Pathol 2002, 161:1247–1253)
Pathological angiogenesis is characteristic of several dis-
ease processes affecting the retina, such as retinopathy
of prematurity, diabetic retinopathy and the exudative
form of age-related macular degeneration (AMD). While
the primary stimulus for the development of retinal neo-
vascularization is hypoxia, molecular signals involved in
the appearance and growth of pathological choroidal
neovascularization are not well defined.1 While vascular
endothelial growth factor (VEGF) overexpression is nec-
essary, alone it is not able to induce growth of choroidal
vessels in the subretinal space through the anatomical
barrier represented by the intact Bruch’s membrane.2
Neovascularization is the result of altered balance be-
tween positive and negative regulators of endothelial ac-
tivation, which leads in turn to basement membrane deg-
radation, endothelial cell migration and proliferation
followed by capillary tube formation.3 Such migratory and
tissue remodeling events are regulated by proteolysis
mediated by matrix metalloproteinases (MMPs) and
serine proteases of the plasminogen/plasminogen acti-
vator system. The activities of the secreted MMPs are
tightly regulated at multiple levels. These include regula-
tion of gene expression at the level of transcription, se-
cretion of inactive proenzymes, capacity of the active
enzyme to be either inhibited by members of the TIMP
(tissue inhibitor of metalloproteases) family, or activated
by membrane-type MMPs (MT-MMPs). As a rule, basal
levels of MMPs are absent or weakly positive in normal
tissues, but increase in response to angiogenic cytokines
as do the components of the plasminogen/plasminogen
activator system.4,9
The precise roles of specific MMPs, plasminogen ac-
tivators, and their inhibitors in ocular pathology are still
being elucidated. Mutations in the TIMP-3 gene give rise
to a rare familial form of macular dystrophy associated
with subretinal neovascularization.5 TIMP-3 is expressed
in human retinal pigment epithelium (RPE), and its accu-
mulation is associated with age-related changes in the
retina in macular degeneration.6,7 The expression of
plasminogen activator inhibitor type I (PAI-1) is neces-
sary for the development of choroidal neovascularization
in a laser-induced model.8
MMP-2 and MMP-9 (gelatinases A and B) are of par-
ticular interest because their substrate specificity in-
cludes type IV collagen, which must be degraded to
facilitate the migration of vascular endothelial cells.
These two MMPs show increased expression in a variety
of tumors or pathological settings.9 Genetic studies in
mice indicate that they are required during angiogenesis.
MMP-2 is implicated in angiogenic switching in subcuta-
neous transplants models of tumor progression,10
whereas MMP-9 is specifically required in a murine
model of pancreatic -cell carcinogenesis.11 MMPs ef-
fects are far from being restricted to extracellular matrix
(ECM) degradation (reviewed in ref. 12). Peptide growth
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factors that are sequestered by ECM proteins become
available once degraded by MMP-9.13 MMPs can in-
crease the bioavailability of VEGF11 but also generate
angiogenesis inhibitors such as angiostatin by cleavage
of plasminogen.14 In the eye, high levels of MMP-9 and
MMP-2 have been measured in human diabetic vitreous
fluids or in epiretinal membranes surgically removed in
case of proliferative diabetic retinopathy.15–17 Choroidal
neovascular membranes surgically removed from pa-
tients suffering from AMD also show strong expression of
these MMPs, suggesting that they could cooperate in the
progression of choroidal angiogenesis.18
In this study we have characterized the temporal and
spatial pattern of MMP-9 expression in a mouse laser-
induced model of choroidal neovascularization using
three different approaches: immunohistochemistry, trans-
genic mice expressing -galactosidase reporter gene
under the dependence of MMP-9 promoter, and RT-PCR
analysis on choroidal neovascular structures microdis-
sected by laser pressure catapulting. To characterize the
relative contribution of MMP-9 to the development of
choroidal angiogenesis, we compared subretinal neo-
vascularization in MMP-9-deficient mice and in wild-type
(WT) controls.
Materials and Methods
Genetically Modified Mice (LacZ Transgene and
MMP-9-Deficient)
Construction of mouse line 7700ExIn-LacZ, which con-
tains 7.7 kb of the 5-flanking region and the first exon
and intron of the MMP-9 gene linked to a -galactosidase
gene, was previously described.19 Promoter activity in
this transgenic line closely parallels the activity of the
endogenous MMP-9 gene during embryonic develop-
ment. Homozygous 7700ExIn-LacZ mice for the trans-
gene were mated together to generate new progeny.
Expression of the transgene was determined in 2% para-
formaldehyde 0.2% glutaraldehyde fixed tissues (15 to
30 minutes), washed three times in PBS, and stained with
buffered 5-bromo-4-chloro-3-indolyl--galactopyrano-
side (X-Gal) solution as described.20 As a positive control
for MMP-9 expression, a thermal injury was applied to a
few mice corneas.21 We used the progeny of heterozy-
gous breeding pairs of mice with targeted disruption of
MMP-9, as described by Vu et al.22 Brothers and sisters
from the same litter were used and genotyped by RT-
PCR.23 Homozygous MMP-9-deficient mice (MMP-9/)
and the corresponding WT mice (MMP-9/) of either
sex22 were used in experiments in which neovascular
membranes were quantified. All of the animals used in
this study were maintained with a 12-hour light/12-hour
dark cycle and had free access to food and water.
Murine Model of Laser-Induced Choroidal
Neovascularization
Animal experiments were performed in compliance with
the Association for Research in Vision and Ophthalmol-
ogy (ARVO) statement for the Use of Animals in Ophthal-
mic and Vision Research. Choroidal neovascularization
was induced in mice by four burns (usually at the 6, 9, 12,
and 3 o’clock positions around the optic disk) using a
green argon laser (532 nm; 50 m diameter spot size;
0.05 seconds duration; 400 mW) as previously de-
scribed.24 Animals (five or more in each group) were
sacrificed at day 2, 3, 5, 10, 14, and 28 for the evaluation
of the kinetic of MMP-9 expression, and at day 14 in the
experiment involving MMP-9/ and WT mice compari-
son. In the latter group, before sacrifice, fluorescein an-
giograms (intraperitoneal injection of 0.3 ml of 1% fluo-
rescein sodium; Ciba) were performed to evaluate the
percentage of laser burns developing late phase hyper-
fluorescent spots (corresponding to the leakage of fluo-
rescein from newly formed permeable capillaries). The
eyes were then enucleated and either fixed in buffered
3.5% formalin solution for routine histology or embedded
in TissueTeK (Miles Laboratories, Naperville, IL) and fro-
zen in liquid nitrogen for cryostat sectioning. Choroidal
neovascularization was quantified as previously de-
scribed.8 Briefly, frozen serial sections were cut through-
out the entire extent of each burn, and the thickest lesions
(minimum of 3/lesion) used for the quantification. Using a
computer-assisted image analysis system (Olympus Mi-
cro Image version 3.0 for Windows 95/NT, Olympus Op-
tical Co. Europe GmBH), neovascularization was esti-
mated by the ratio (B/C) of the thickness from the bottom
of the pigmented choroidal layer to the top of the neo-
vascular membrane (B) to the thickness of the intact-
pigmented choroid adjacent to the lesion (C). Due to the
small size of most lesions, that method was preferred to
surface estimation for its independence in relation to
oblique sections, its reproducibility and correlation with
fluorescein angiograms results.
Immunohistochemistry
Cryostat sections (5 m thick) were fixed in paraformal-
dehyde 1% in 0.07 mol/L phosphate-buffered saline
(PBS) pH 7.0 for 5 minutes or in acetone for 10 minutes at
room temperature and then incubated with the primary
antibody. Antibodies raised against type IV collagen
(guinea pig polyclonal antibody produced in our labora-
tory; diluted 1/100), mouse MAC-1 (monoclonal antibody
anti CD-11b R-phycoerythrin labeled, PharMingen, San
Diego, CA; diluted 50 g/ml), mouse neutrophils (rat
polyclonal antibody, Serotec, Oxford, UK; diluted 1/200)
and mouse PECAM (rat monoclonal antibody, PharMin-
gen, San Diego, CA; diluted 1/20) were incubated for 1
hour at room temperature, whereas antibodies to MMP-9
(rabbit anti-mouse antibody, diluted 1/200, a generous
gift from P. Carmeliet, Katholieke Universiteit Leuven,
Belgium) were incubated overnight. The sections were
washed in PBS (3  10 minutes) and appropriate sec-
ondary antibodies conjugated to fluorescein-isothiocya-
nate (FITC) or Texas red were added: swine anti-rabbit
IgG (Dako, Glostrup, Denmark; diluted 1/40), monoclonal
anti-guinea pig IgG (Sigma; diluted 1/40) or rabbit anti-rat
IgG (Sigma; diluted 1/40) were applied for 30 minutes.
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For double immunofluorescence-labeling studies, sec-
tions were first incubated with the two primary antibodies,
and then with FITC- and Texas red-conjugated second-
ary antibodies. After three washes in PBS for 10 minutes
each and a final rinse in 10 mmol/L Tris-HCl buffer, pH
8.8, labeling was analyzed under an inverted microscope
equipped with epifluorescence optics. MAC-1 and neu-
trophils sections were counterstained with bis-benzimide
(20 mg/100 ml) for 15 minutes. Specificity of staining was
assessed by substitution of nonimmune serum for pri-
mary antibody (in the case of MMP-9 protein, MMP-9/
tissues were used as a negative control).
Laser Pressure Catapulting (LPC) and RT-PCR
Eight to 10 serial frozen sections were mounted directly
onto a 1.35-m thin polyethylene foil (PALM, Wolfrat-
shausen, Germany). The supporting membrane was
mounted onto the glass slide using the Microbeam-MO-
MeNT technique.25 The membrane-covered slides can
be stored at room temperature until needed. The Robot-
Microbeam (PALM) focused the laser (337 nm) on the
specimen with appropriate energy settings enabling the
catapulting of the entire selected area into the Microfuge
cap. The entire subretinal choroidal neovascularization
area and an adjacent intact chorioretinal zone (control)
were microdissected separately on frozen sections (10
m thick) at selected intervals after laser burn (days 3, 5,
10, 14, and 40). The specimens were covered with 100 l
of lysis buffer and total RNA isolation was performed with
the PUREscript RNA-isolation Kit (BIOzym, Landgraaf, The
Netherlands) according to the manufacturer’s protocol. To-
tal RNA was dissolved in a 10-l RNA hydration solution
supplied by the manufacturer. 28S rRNA were amplified with
an aliquot of 1 l of total RNA using the GeneAmp Thermo-
stable rTth reverse transcriptase RNA PCR kit (Perkin Elmer)
and three pairs of primers (Gibco BRL-Life Technologies):
sense: 5-GTTCACCCACTAATAGGGAACGTGA-3 and re-
verse: 5-GGATTCTGACTTAGAGGCGTTCAGT-3for 28S
mRNA; sense: 5-AGACCTGAAAACCTCCAACCTCAC-3
and reverse: 5-TGTTATGATGGTCCCACTTGAGGC-3 for
MMP-9; and sense: 5-AGATCTTCTTCTTCAAGGACCG-
GTT-3 and reverse: 5-GGCTGGTCAGTGGCTT-
GGGGTA-3 for MMP-2. Reverse transcription was per-
formed at 70°C for 15 minutes followed by 2 minutes of
incubation at 95°C for denaturation of RNA-DNA heterodu-
plexes. Amplification started by 15 seconds at 94°C, 20
seconds at 68°C and 10 seconds at 72°C for MMP-2 and
28S (45 cycles for MMP-2 and 30 cycles for 28S) or by 15
seconds at 94°C, 20 seconds at 60°C, and 15 seconds at
72°C for MMP-9 (45 cycles) and terminated by 2 minutes at
72°C. RT-PCR products were resolved on 2% agarose gels
and analyzed using a Fluor-S MultiImager (BioRad) after
staining with Gelstar (FMC BioProducts) dye. The expected
size for RT-PCR products were 212 bp for 28S, 225 bp for
MMP-2, and 262 bp for MMP-9, respectively.
Gelatin Zymography Assay
Choroidal neovascularization was induced in mice by 30
burns as described above. Animals were sacrificed at
day 3 and the eyes were enucleated. The posterior seg-
ments were cut out and immediately snap frozen in liquid
nitrogen. Frozen tissues were then pulverized in liquid
nitrogen, homogenized in buffer (0.1 mol/L Tris-HCl pH
8.1, 0.4% Triton X-100) and centrifuged for 20 minutes at
5000  g. The pellets were discarded. Aliquots of super-
natants were mixed with SDS sample buffer and electro-
phoresed directly as previously described.26
Statistical Analysis
Data were analyzed with GraphPad Prism 3.0 (San Di-
ego, CA). The Mann-Whitney test was used to determine
whether there were significant (P  0.05) differences
between WT and MMP-9/ mice.
Results
MMP-9 Induction and Evolution
The argon laser induced trauma at the level of outer
retina, retinal pigment epithelium and Bruch’s membrane,
giving rise to choroidal neovascularization under the ret-
ina, similar to that observed in exudative form of AMD.
Histological analysis and immunostaining with anti-PE-
CAM and anti-collagen type IV antibodies confirmed the
presence of newly formed capillaries taking typically the
form of “mushroom-like” areas (identifiable already at day
5) over the normal choroid layer.
Immunohistochemical staining demonstrated the pres-
ence of MMP-9 protein exclusively at the site of laser-
induced injury (retinal pigment epithelium and choroidal
layer) and not in intact adjacent areas (Figure 1A). The
intensity of staining was maximal at day 3 (before any
visible outgrowth of newly formed microvessels), weak at
day 5 (Figure 1B) and completely absent thereafter. No
staining was observed at any location in MMP-9/ mice
(not shown). The staining in the positive control (thermal
injury of the cornea) was also maximal at day 3 and
present selectively in the corneal stroma adjacent to the
burned area (Figure 1C) as previously described.27
MMP-9 promoter activity, mapped with -galactosi-
dase reporter gene, was undetectable in the retina or in
the cornea of intact eyes. In treated eyes, it did not strictly
colocalize either spatially or temporally with MMP-9 pro-
tein. The product of the -galactosidase reaction could
not be detected before day 5 (Figure 1D) both in the
chorioretinal neovascular membrane (Figure 1E) and in
the corneal epithelium (positive control, Figure 1F). It was
only occasionally detected after day 5. The product of the
-galactosidase reporter gene was localized at the grow-
ing edge of the neovascular reaction over the plane of the
pigment epithelium. The activity of MMP-9 promoter in the
lesions at day 5 coincided with the first appearance of
macrophages detected by immunohistochemistry (Fig-
ure 2,A–D). Polymorphonuclear cells were absent at day
5 but infiltrated the lesions at an earlier stage (Figure 2, E
and F).
RT-PCR analysis applied on microdissected neovas-
cular choroidal membranes extracted by laser pressure
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catapulting at different time endpoints confirmed MMP-9
mRNA expression only at day 5 after photocoagulation,
similarly to the results obtained with the -galactosidase
transgene (Figure 3). The retinal specimens microdis-
sected from neighboring intact chorioretinal areas were
negative for MMP-9 mRNA throughout the study period.
This contrasted with the expression of MMP-2, which was
relatively constant from day 3 to day 14 with a small peak
at day 10 (Figure 3, center line). Unlike MMP-9, MMP-2
expression was not restricted to the choroidal neovascu-
lar area and was also detected, at a lower level, outside
the impact zone in intact chorioretinal tissue.
The activities of MMP-2 and MMP-9 posterior eyes
segments of normal mice and in neovascular choroidal
membranes induced by laser were analyzed by gelatin
zymography. The latent form of MMP-2 was detected in
all tissue extracts (Figure 4). Its level was however more
important in laser induced membranes which additionally
contained active MMP-2. MMP-9 activity was weakly de-
tected in intact eyes, whereas higher levels were found in
laser treated eyes.
Choroidal Neovascularization in Vivo in
MMP-9/ and WT Mice
To determine whether the absence of MMP-9 influences
choroidal neovascularization in vivo, we first evaluated
the incidence of leaking spots on fluorescein angiograms
performed on day 14. Newly formed microvessels with
significant leakage of fluorescein were observed in 75%
of the laser-induced lesions. The incidence of detected
leaking spots was not significantly different in MMP-9/
mice compared to their WT controls (not shown). Neo-
Figure 1. Temporal pattern of protein and MMP-9 mRNA presence after laser-induced choroidal neovascularization. A—C: Immunolocalization of MMP-9 (red)
in ocular frozen sections counterstained with collagen type IV antibody (green) at day 3 (A), day 5 (B) after laser injury of the Bruch’s membrane, and in corneas
subjected to thermal injury (C) (positive control). D–F: Mapping of MMP-9 expression using transgene mice expressing -galactosidase (blue) under the
dependence of MMP-9 promoter at day 3 (D) and day 5 (E) in the retina and at day 5 in the cornea (F). White arrows localize the laser impact. The neural retina
(ret), retinal pigment epithelium (rpe), choroidal layer (ch), corneal epithelium (ep), corneal stroma (str) and descemet membrane (de) are indicated. Original
magnification, 100.
Figure 2. Immunolocalization of mononuclear and polymorphonuclear inflammatory cells during the course of choroidal neovascular membrane development
after laser injury of the choroid. Mac-1 immunostaining (red) on frozen sections counterstained with bis-benzimide (blue) is absent in the choroid at day 3 (A,
B), and appears in the impact at day 5 (C, D). Neutrophils (red) are present at day 3 (E, F), but not at day 5 (data not shown). White arrows localize the laser
impact. Original magnifications: A, C, 100; B, D, E, 400; F, 630.
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vascularization was then estimated by immunostaining
with anti-type IV collagen and anti-PECAM antibodies
and, histologically, by measuring, on serial sections, the
maximal height of the lesion above the choroidal layer
observed in neighboring intact zones (Figure 5). Choroi-
dal neovascularization at the site of laser-induced trauma
was more restricted reaction in MMP-9/ mice than in
WT mice. This was quantified by determining the B/C
ratio between total thickness of lesions (B, from the bot-
tom of the choroid to the top of the neovascular area) to
the thickness of adjacent normal choroid (C), and a 20%
reduction of the B/C ratio was consistently observed in
MMP-9-deficient mice (P  0.001) as compared to WT
mice (Figure 6).
Discussion
The matrix metalloproteinases (MMPs) are able to de-
grade components of the extracellular matrix, inhibitors,
and other pericellular proteins and promote angiogenesis
and tumor invasion. MMP-2 and MMP-9 have been of
particular interest in angiogenesis research because
Figure 3. MMP-2 and MMP-9 expression are differentially modulated during
the progression of choroidal neovascular reaction in a murine laser-induced
model. Laser pressure catapulting followed by RT-PCR analysis on microdis-
sected choroidal new vessels (I) and on adjacent (control) intact chorioreti-
nal tissue (C) from day 3 to day 40. Molecular weight numbers (bp) are
shown at left. The control at day 10 is missing due to limited amount of
extracted RNA.
Figure 4. Zymographic analysis of MMP-2 and MMP-9 in tissues extracted
either from posterior eyes segments with laser-induced neovascularization (I,
day 3) or intact eyes (C) of three different mice. As positive control, medium
conditioned by human HT1080 cells was included. Positions of MMP-2 and
MMP-9 are indicated by arrows.
Figure 5. Histological analysis after laser treatment. Hematoxylin-eosin staining of a representative area of choroidal neovascularization at the site of laser-induced
trauma in WT mice (A), and a more restricted reaction in MMP-9/ mice (B). Immunofluorescence labeling of new vessels in WT (C) or in MMP-9/ mice (D)
analyzed 14 days after laser photocoagulation. New vessels were detected with anti-mouse anti-collagen type IV antibody (green) and anti-mouse anti-PECAM
antibody (red). The neural retina (ret), retinal pigment epithelium (rpe), and choroidal layer (ch) are indicated and the neovascular area is arrowed. White
arrows localize the laser impact. Original magnification, 200
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their substrate specificity includes type IV collagen, a
major component of basement membranes and of the
subretinal Bruch’s membrane. However, MMP action can
be both proangiogenic and antiangiogenic. While MMP-9
regulates the bioavailablity of VEGF,11 stimulating angio-
genesis, MMPs also generates antiangiogenic factors
and degrades basement membranes, which may desta-
bilize the newly formed blood vessels, thus trimming
back and limiting the extent of angiogenesis.28
Since MMP-9 expression has been demonstrated in
human proliferative ischemic chorioretinopathies29 and in
experimental ocular models,30 the aim of our investiga-
tion was to determine whether MMP-9 plays a role in
laser-induced choroidal neovascularization, a model sim-
ilar to the exudative AMD, the most sight-devastating
form of human AMD.
MMP-9 mRNA expression was mapped using trans-
genic mice expressing -galactosidase reporter gene
under the dependence of MMP-9 promoter. RT-PCR
analysis was performed on choroidal neovascular struc-
tures microdissected from serial sections by laser pres-
sure catapulting. To our knowledge, this is the first report
applying microdissection techniques to study gene ex-
pression in experimental subretinal neovascularization.
These two approaches cooperatively demonstrated that
the local expression of MMP-9 mRNA is restricted to day
5 after laser burn. Although resident cells might also
produce MMP-9, mRNA detection coincides perfectly
with the appearance of macrophages within the neovas-
cular reaction. This suggests that inflammatory cells are a
predominant provider of MMP-9, as found previously in
tumor models.31 Indeed, an angiogenic role for macro-
phages infiltrating choroidal new vessels has already
been reported.32 A previous study using krypton laser in
rats to induce choroidal neovascularization did not find a
change in the expression of MMP-9 using in situ hybrid-
ization.33 Differences in methodology, animal model and
sensitivity of the techniques and the very narrow time
window of expression probably explain these apparent
discrepancies.
It is worth noting that inflammatory cells containing
preformed MMP-9 in intracellular granules could also
contribute to the development of the lesions. Since the
contribution of these providers of MMP-9 protein would
not be detected by the MMP-9 evaluation at the mRNA
levels, it was therefore important to compare protein and
mRNA expressions. At the protein level, MMP-9 activity
was observed with zymography and was immunohisto-
chemically localized in the laser-induced lesion already
at day 3, before local mRNA expression was detected.
Thus MMP-9 probably first arose from early recruitment
and degranulation of neutrophils before a transcriptional
induction of its local expression and that preformed pro-
tein might represent the major source of active MMP-9.
The pattern of MMP-2 expression obtained by RT-PCR
on microdissected samples is different from that of
MMP-9. MMP-2 was constantly expressed throughout the
study period both in the choroidal neovascular mem-
brane and in control adjacent intact areas, with a relative
peak of expression at day 10 whose significance is at
present unclear. These data confirm the clear different
regulation pattern of MMP-2 and MMP-9.
MMP-9 Contributes to Choroidal
Neovascularization in the Murine Laser-Induced
Model
Angiogenesis determined by immunohistochemistry and
quantitative histology was significantly reduced in MMP-
9-deficient animals compared to WT controls. The pattern
of MMP-2 expression demonstrated that MMP-2 did not
compensate for the deficiency of MMP-9. Our results
provide for the first time evidence that MMP-9 contributes
to choroidal neovascularization induced by laser al-
though they do not distinguish whether MMP-9 exerts its
role directly or through the release and/or activation of
other angiogenic factors such as VEGF.11,34 However,
the magnitude of angiogenesis inhibition was much less
important than that observed previously in the same
model applied on mice deficient for plasminogen activa-
tor type I.8 This in turn suggests that MMP-9 is not the
only pathway for rendering angiogenic factors bioavail-
able, which clearly occurs for VEGF-dependent angio-
genesis later in tumor progression.11 Nevertheless the
MMP-9 induction restricted to day 5 after laser-induced
rupture of the Bruch’s membrane contributed to the se-
verity of pathological choroidal neovascularization. Taken
together with the previous work on PAI-1, these data
indicate that a balance of both positive and negative
regulation of proteolysis by more than one enzyme sys-
tem are critical to overall neoangiogenesis. One implica-
tion of our observations is that combination of MMP-9
inhibitors with other anti-angiogenic agents may be a
promising strategy.
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